NCT07285538Recruiting
Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer
A Prospective Interventional Study of Stereotactic Body RadioTherapy (SBRT) With Continuous Tracking for Inoperable Patients With Primary and Secondary Renal Cancer (SBRTRC)
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This is a prospective, interventional, monocentric, clinical study of Stereotactic Body Radiation Therapy (SBRT) for primary or secondary renal tumors, delivering from 25-26 Gy/1 fraction to 42-48 Gy/3-4 fractions or 40-50 Gy/5 fractions (standard prescriptions for the internationl guidelines, according to tumor size), using a robotic accelerator -CyberKnife® (Accuray, Sunnyvale, CA)-, with fiducial-tracking, to observe the acute and late toxicity reduction (as primary objectives), due to the maximum precision of the treatment. Secondary objectives are Local Relpase-Free Survival (LRFS), Regional Relapse-Free Survival (RRFS), Distant Metastasis-Free Survival (DMFS), Disease-Free Survival (DFS), Cancer Specific Survival (CSS), Overall Survival (OS) and Quality-of-Life (QoL). A total of 60 participants are expected to be enrolled over four years, and the follow-up of enrolled patients will be three years.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 26 Nov 2025
- Start date
- 14 Sept 2026
- Primary completion date
- 15 Jan 2033
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Kidney cancer
- NCT number
- NCT07285538
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 14 Sept 2026 to the primary completion date, 15 Jan 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Psychiatric or other disorders that may prevent the patient from signing informed consent
- Previous invasive cancer, except for skin cancer (excluding melanoma) unless the patient has been disease-free for at least 3 years (e.g., carcinoma in situ of the oral cavity or bladder)
- Collagen diseases
- Sjogren's syndrome
Age
- Patients aged \< 18 years
Other
- Tumors \> 10 cm
- PS ECOG ≥3
- Pregnant women
Who the study is looking for
- Histological or clinical diagnosis of primary or secondary kidney tumors
- Patients aged ≥18 years
- Signed informed consent
- Tumor up to 10 cm in the greatest diameter (sum of diameters in case of multiple lesions)
- PS (ECOG) ≤2
- No prior local radiotherapy
- Fertile women using contraception methods previously initiated (a pregnancy test will be prescribed)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.